

PATENT & TRADEMARK OFFICE-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 01107.00466	SERIAL NUMBER tba 10/816932
	APPLICANT Jonathan Schneck et al.	
	FILING DATE April 5, 2004	GROUP ART UNIT 1642 (prior) 11044

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
MD	5,420,244	5/30/95	Rudolph et al.			
KMD	5,635,363	6/3/1997	Altman et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES/NO
MD	WO 94/19473A1	9/1/94	WIPO			
MD	WO 94/26903 A2	11/24/94	WIPO			
MD	WO 94/28871 A1	12/22/94	WIPO			
MD	WO 96/20215 A2	7/4/96	WIPO			
MD	WO 97/35991 A1	10/2/97	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MD	Casares et al. "Engineering and Characterization of a Murine MHC Class II-Immunoglobulin Chimera Expressing an Immunodominant CD4 T Viral Epitope" Protein Engineering, Vol. 10, No. 11, November 1997, pages 1295-1301
MD	Kalandadze et al. "Expression of Recombinant HLA-DR2 Molecules" The Journal of Biological Chemistry, Vol 271, No. 33, August 16, 1996, pp. 20156-20162
MD	Scott et al. "Role of Chain Pairing for the Production of Functional Soluble IA Major Histocompatibility complex Class II Molecules" J. Exp. Med. Vol. 183, May 1996, pp. 2087-2095

EXAMINER Marianne D.	DATE CONSIDERED 12/16/05
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	

PATENT & TRADEMARK OFFICE-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY DOCKET NO. 001107.00466	SERIAL NUMBER 10/810,937
	APPLICANT Jonathan Schneck et al.	
	FILING DATE April 5, 2004	GROUP ART UNIT 1642 (prior) 16149

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
MSD	5,574,205	11/12/1996	Kuchersapati et al.			
MSD	5,679,641	10/21/1997	Melief et al.			
MSD	5,820,866	10/13/1998	Kappler et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES/NO
MSD	WO 99/09064 A1	2/25/1999	WIPO			
MSD	WO 93/24525 A1	12/9/1993	WIPO			
MSD	WO 94/24290 A1	10/27/1994	WIPO			
MSD	WO 98/03552 A2	1/29/1998	WIPO			
MSD	WO 97/44667 A2	11/27/1997	WIPO			X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MSD	Gnjatic et al. "Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules" Eur. J. Immunol. 25(6):1638-42 (June 1995) (Abstract)
MSD	Kozono et al. "Production of soluble MHC class II proteins with covalently bound single peptides" Nature 369(6476):151-54(May 1994)
MSD	Lee et al. "Functional cell surface expression by a recombinant single-chain class I major histocompatibility complex molecule with a cis-active beta 2-microglobulin domain" Eur. J. Immunol. 24(11):2633-39 (Nov. 1994) (Abstract)
MSD	Lepley et al. "Biochemical and Functional Characterization of Soluble Multivalent MHC L'/Fcγ1 and L'/Fcγ2 Chimeric Proteins Loaded with Specific Peptides" Transplantation, 63:765-774 (March 15, 1997)
MSD	Lone et al. "In Vitro Induction of Specific Cytotoxic T Lymphocytes Using Recombinant Single-Chain MHC Class I/Peptide Complexes" J. Immunother. 21(4):283-294 (1998)
MSD	Mage et al. "A recombinant, soluble, single-chain class I major histocompatibility complex molecule with biological activity" PNAS 89(22):10658-62 (Nov. 1992)
MSD	McCarty et al. "Targeting p53 for adoptive T-cell immunotherapy" Cancers Res. 58, 2601-05 (June 15, 1998) (Abstract)
MSD	McCarty et al. "An HLA-restricted, p53 specific immune response from HLA transgenic p53 knockout mice" Ann Surg Oncol 1998 Jan-Feb;5(1):93-9
MSD	Mottez et al. "Cells Expressing a Major Histocompatibility Complex Class I Molecule with a Single Covalently Bound Peptide are Highly Immunogenic" J. Exp. Med., 181:493-502 (Feb. 1995)
MSD	White et al. "Soluble Class I MHC with β2-Microglobulin Covalently Linked Peptides: Specific binding to a T Cell Hybridoma" J. Immunol. 162(5):2671-2676 (March 1999)
MSD	Zimmerman et al. "Expression of a Functional Chimeric Ig-MHC Class II Protein" J. Immunol. 148(1):272-6 (Jan. 1992)

EXAMINER [Signature]	DATE CONSIDERED 12/16/05
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	

PATENT & TRADEMARK OFFICE-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 001107.00466	SERIAL NUMBER 101816132
	APPLICANT Jonathan Schneck et al.	
	FILING DATE April 5, 2004	GROUP ART UNIT 1642 (prior) 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
MW	5,869,270	2/9/1999	Rhode et al.			
MW	6,015,884	1/18/2000	Schneck et al.			
MW	5,652,342	7/29/1997	Zimmerman et al.			
MW	6,011,146	1/4/2000	Mottez et al.			
MW	5,284,935	2/8/1994	Clark et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES/NO
MW	WO 93/17095 A1	9/2/1993	WIPO			
MW	WO 98/10284 A1	3/12/1998	WIPO			
MW	WO 99/50637 A2	10/7/1999	WIPO			
	EP 0 352 761 A2	07/25/1989	Europe			
MW	WO 98/06749 A2	2/19/1998	WIPO			
MW	WO 99/64597 A1	12/16/1999	WIPO			
MW	WO 99/42597	8/26/1999	WIPO			

No English
Abstract
No English
Abstract

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MW	Nijman et al. "Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides" J. Immunother 1993 Aug;14(2):121-6 (Abstract)
MW	Vierboom et al. "Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes" J. Exp Med 1997 Aug 29;186(5):695-704 (Abstract)
MW	Melief and Kast "T-cell immunotherapy of cancer" Res Immunol 1991 Jun-Aug; 142(5-6):425-9 (Abstract)
MW	DeLeo "p53-based immunotherapy of cancer" Crit Rev Immunol 1998;18(1-2):29-35 (Abstract)
MW	Bertholet et al. "Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides" Eur J Immunol 1997 Mar;27(3):798-801 (Abstract)
MW	Biggs et al. "Targeting p53 as a general tumor antigen" Proc Natl Acad Sci USA 1995 Dec 19;92(26):11993-7 (Abstract)
MW	Mottez et al. "A single-chain murine class I major transplantation antigen" Eur J Immunol 1991 Feb;21(2):467-71

EXAMINER <i>Kraname</i>	DATE CONSIDERED 12/16/05
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	

PATENT & TRADEMARK OFFICE-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 001107.00466	SERIAL NUMBER 10816732
	APPLICANT Jonathan Schneck et al.	
	FILING DATE April 5, 2004	GROUP/ART UNIT #642 (prior) 16

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
MD	5,116,964	5/26/92	Capon et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES/NO
MD	WQ 96/04314 A1	2/15/96	WIPO			
MD	WO 93/10220 A1	5/27/93	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MD	J. Dal Porto et al. "A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations" Proceedings of the National Academy of Sciences Vol. 90, 3/93 pages 6671-6675 1993
MD	T. Johansen et al. "Potent inhibition of alloreactive T cells by nanomolar concentrations of a divalent soluble class I MHC molecule" The Journal of Immunology, Vol. 150, No. 8, part 2, April 15, 1993, page 83A, Abstract.
MD	C. Gregoire et al. "Engineered secreted T-cell receptor alpha-beta heterodimers" Proceedings of the National Academy of Sciences Vol. 88, September 1991, pages 8077-8081
MD	D. Eilat et al. "Secretion of a soluble, chimeric gamma-delta T-cell receptor-immunoglobulin heterodimer" Proceedings of the National Academy of Sciences, Vol. 89, August 1992, pages 6871-6875
MD	S. Weber et al. "Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor" Nature, Vol. 356, April 30, 1992, pages 792-796
MD	H-C Chang et al. "A general method for facilitating heterodimeric pairing between two proteins: Application to expression of alpha and beta T-cell receptor extracellular segments" Proceedings of the National Academy of Sciences Vol. 91, November 1994, pages 11408-11412
MD	S. O'Herrin and J.P. Schneck "Expression and analysis of soluble MHC- and TCR-immunoglobulin super dimers" The FASEB Journal, Vol. 10, No. 6, April 30, 1996 page A1473
MD	J. Schneck et al. "Specific inhibition of graft rejection by soluble MHC superdimers" The FASEB Journal, Vol. 10, No. 6, April 30, 1996, page A1473
MD	M. Lebowitz et al. "Specificity of soluble 2C TcR/Ig superdimers for peptide/MHC complexes" The FASEB Journal, Vol. 10, No. 6, April 30, 1996, page A1178
MD	J. D. Altman et al. "Phenotypic Analysis of Antigen-Specific T Lymphocytes" Science, Vol. 274, October 4, 1996, pages 94-96

EXAMINER 	DATE CONSIDERED 12/16/05
EXAMINER: Initial citation if reference was considered. Draw line through citation if not in conformance to MPEP 609 and not considered. Include copy of this form with next communication to applicant.	